SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

Highlights SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Market Closed - Hong Kong S.E. Other stock markets 04:08:11 2024-05-08 EDT			5-day change	1st Jan Change
18.16 ^HKD	+0.11%		+1.23%	+30.46%

04-18	Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31	MT
04-01	SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31	04-18	MT
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit	04-01	MT
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China	01-31	CI
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer	11-07	CI
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China	11-06	CI
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1	23-08-18	MT
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China	23-07-04	CI
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China	23-07-02	CI
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.	23-06-06	CI
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022	23-05-25	CI
SciClone Pharmaceuticals Limited's Equity Buyback announced on May 20, 2022, has expired.	23-05-24	CI
Sciclone Pharmaceuticals Limited Declares Final Dividend for the Year Ended December 31, 2022, Payable on 28 June 2023	23-03-30	CI
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Sciclone Pharmaceuticals Limited Announces Nmpa Approval of Ind Application for Vaborem	23-03-19	CI
SciClone Pharmaceuticals Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration	22-12-27	CI
SciClone Pharmaceuticals Limited Announces NMPA Approval of Biologics License Application of Danyelza for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China	22-12-08	CI
EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals	22-10-06	CI
A. Menarini Asia-Pacific Holdings Pte. Ltd., and SciClone Pharmaceuticals Limited Enters into Licensing Agreement to Develop and Commercialize Vaborem	22-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Highlights

Filters